NEW YORK, June 14, 2017 /PRNewswire/ -- Rosen Law Firm, a
global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of ImmunoCellular
Therapeutics, Ltd. securities (NYSEMKT: IMUC) from May 1, 2012 through December 11, 2013, inclusive (the "Class Period"). The lawsuit seeks to recover damages for ImmunoCellular
investors under the federal securities laws.
To join the ImmunoCellular class action, go to http://rosenlegal.com/cases-1115.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU
RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The complaint alleges that defendants during the Class Period made false and misleading statements and/or failed to disclose
that ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote ImmunoCellular,
which led the market to believe that ImmunoCellular's clinical studies for its product candidate ICT-107 was going well. As a
result of this scheme, ImmunoCellular's share price was artificially inflated. On April 10, 2017,
the Securities and Exchange Commission announced enforcement actions against ImmunoCellular, as well as other individuals and
entities, for engaging in stock promotion schemes.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than
June 30, 2017. A lead plaintiff is a representative party acting on behalf of other class members
in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1115.html or to discuss your rights or
interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and
shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder
Services for the number of securities class action settlements annually obtained for investors.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/equity-alert-rosen-law-firm-announces-filing-of-securities-class-action-lawsuit-against-immunocellular-therapeutics-ltd--imuc-300474059.html
SOURCE Rosen Law Firm, P.A.